Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073

ABSTRACT Daily oral tenofovir disoproxil fumarate (TDF)-emtricitabine (FTC) is a safe and effective intervention for HIV preexposure prophylaxis (PrEP). We evaluated the performance of a qualitative assay that detects 20 antiretroviral (ARV) drugs (multidrug assay) in assessing recent PrEP exposure (detection limit, 2 to 20 ng/ml). Samples were obtained from 216 Black men who have sex with men (208 HIV-uninfected men and 8 seroconverters) who were enrolled in a study in the United States evaluating the acceptability of TDF-FTC PrEP (165 of the uninfected men and 5 of the seroconverters accepted PrEP). Samples from 163 of the 165 HIV-uninfected men who accepted PrEP and samples from all 8 seroconverters were also tested for tenofovir (TFV) and FTC using a quantitative assay (detection limit for both drugs, 0.31 ng/ml). HIV drug resistance was assessed in seroconverter samples. The multidrug assay detected TFV and/or FTC in 3 (1.4%) of the 208 uninfected men at enrollment, 84 (40.4%) of the 208 uninfected men at the last study visit, and 1 (12.5%) of the 8 seroconverters. No other ARV drugs were detected. The quantitative assay confirmed all positive results from the multidrug assay and detected TFV and/or FTC in 9 additional samples (TFV range, 0.65 to 16.5 ng/ml; FTC range, 0.33 to 14.6 ng/ml). Resistance mutations were detected in 4 of the 8 seroconverter samples. The multidrug assay had 100% sensitivity and specificity for detecting TFV and FTC at drug concentrations consistent with daily PrEP use. The quantitative assay detected TFV and FTC at lower levels, which also might have provided protection against HIV infection.

[1]  J. Blankson,et al.  Natural control of HIV infection in young women in South Africa: HPTN 068 , 2018, HIV clinical trials.

[2]  T. Sandfort,et al.  Accuracy of Self-Reported HIV Status Among African Men and Transgender Women Who Have Sex with Men Who were Screened for Participation in a Research Study: HPTN 075 , 2018, AIDS and Behavior.

[3]  R. Gandhi.  Preexposure Prophylaxis for the Prevention of HIV , 2018 .

[4]  O. Laeyendecker,et al.  Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043) , 2017, Journal of acquired immune deficiency syndromes.

[5]  R. Grant,et al.  Effectiveness and safety of oral HIV preexposure prophylaxis for all populations , 2016, AIDS.

[6]  H. Jessen,et al.  HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans , 2016, Infection.

[7]  David Thompson,et al.  On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. , 2015, The New England journal of medicine.

[8]  J. Justman,et al.  Antiretroviral Drug Use in a Cohort of HIV-Uninfected Women in the United States: HIV Prevention Trials Network 064 , 2015, PloS one.

[9]  O. Laeyendecker,et al.  Antiretroviral Drug Use and HIV Drug Resistance Among HIV-Infected Black Men Who Have Sex With Men: HIV Prevention Trials Network 061 , 2015, Journal of acquired immune deficiency syndromes.

[10]  A. Hughes,et al.  Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq , 2014, Retrovirology.

[11]  R. W. Jenny,et al.  Adding value to antiretroviral proficiency testing. , 2014, Bioanalysis.

[12]  J. Baeten,et al.  HIV Protective Efficacy and Correlates of Tenofovir Blood Concentrations in a Clinical Trial of PrEP for HIV Prevention , 2014, Journal of acquired immune deficiency syndromes.

[13]  Myron S. Cohen,et al.  The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. , 2014, Clinica chimica acta; international journal of clinical chemistry.

[14]  K. Mayer,et al.  Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). , 2013, The Journal of infectious diseases.

[15]  C. Hendrix,et al.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial , 2013, The Lancet.

[16]  M. Carrieri,et al.  Assessing adherence to antiretroviral therapy in randomized HIV clinical trials: a review of currently used methods , 2013, Expert review of anti-infective therapy.

[17]  A. Minnis,et al.  Methodological Lessons from Clinical Trials and the Future of Microbicide Research , 2013, Current HIV/AIDS Reports.

[18]  J. Justman,et al.  MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments , 2013, PloS one.

[19]  A. Adimora,et al.  HIV Acquisition Among Women From Selected Areas of the United States , 2013, Annals of Internal Medicine.

[20]  J. Baeten,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[21]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[22]  Douglas J. Taylor,et al.  Preexposure prophylaxis for HIV infection among African women. , 2012, The New England journal of medicine.

[23]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[24]  R. Di Santo,et al.  HIV type 1 integrase inhibitors: from basic research to clinical implications. , 2008, AIDS reviews.

[25]  D. Harris,et al.  Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir-Ritonavir in Adolescents and Young Adults with Human Immunodeficiency Virus Infection , 2007, Antimicrobial Agents and Chemotherapy.

[26]  G. Chittick,et al.  Steady‐State Pharmacokinetics of Emtricitabine and Tenofovir Disoproxil Fumarate Administered Alone and in Combination in Healthy Volunteers , 2007, Journal of clinical pharmacology.

[27]  M. Chesney,et al.  The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  K. Mayer,et al.  Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066). , 2016, AIDS research and human retroviruses.

[29]  S. Buchbinder,et al.  Nondisclosure of HIV status in a clinical trial setting: antiretroviral drug screening can help distinguish between newly diagnosed and previously diagnosed HIV infection. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  C. Bova,et al.  A Proposal for Quality Standards for Measuring Medication Adherence in Research , 2012, AIDS and Behavior.